drugset / Trial / NCT02504008

CREATE-1: A Study to Assess the Efficacy and Safety of AXS-02 in Patients With CRPS-1

NCT02504008

Phase 3 Unknown 190 enrolled Axsome Therapeutics, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled, 24-week study to evaluate the efficacy and safety of AXS-02 in patients with CRPS-I.

Timeline

Start
2015-07
Primary completion
2019-01
Completion
2019-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Zoledronate Other / unclassified Oral